
Neuphoria Therapeutics Inc. (NEUP) stock drew heightened attention from retail investors after prominent investor Lynx1 Capital Management LP increased its stake by acquiring 639,110 shares.
The share purchase, made on October 21, was disclosed in a Securities and Exchange Commission (SEC) filing.
The shares were bought at prices ranging from $4.96 to $5.20, with an average cost of $5.137 per share. In total, Lynx1 Capital spent $3.3 million to expand its position.
Following this acquisition, the investment firm now controls 875,328 shares of Neuphoria Therapeutics. The transaction highlights growing investor confidence in Neuphoria’s pipeline and market potential.
Neuphoria Therapeutics’ stock traded over 64% higher on Friday morning and was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.